Practical aspects of human immunodeficiency virus multiresistance in modern clinical practice

Abstract

The article presents an analysis of a special clinical case: a male patient with perinatal HIV infection and the development of HIV multi-resistance to antiretroviral drugs. Multiple corrections of treatment regimens were carried out based on the results of determining HIV resistance to the antiretroviral drugs used. The treatment regimen included antiretroviral drugs with fundamentally new mechanisms of action for HIV, not registered in the Russian Federation. However, to date, in the patient with more than twenty years of experience in antiretroviral therapy, it has not been possible to achieve immunological and virological efficacy of treatment. There continues to be a persistent decrease in the indicators of the immune status and an increase in the viral load of HIV in the blood, the appearance of clinical symptoms of opportunistic diseases indicating the progression of HIV infection and an unfavorable vital prognosis, despite the use of various combinations of antiretroviral drugs. This observation demonstrates the difficulties in choosing an effective antiretroviral therapy, taking into account the established sensitivity of HIV to antiretroviral drugs and the possibility of their progredient administration. It is certainly necessary to analyze all ART regimens with the results of HIV resistance to antiretroviral drugs using to improve the effectiveness of therapy is in each case.

Keywords

human immunodeficiency virus / HIV infection / antiretroviral therapy / HIV resistance / antiretroviral drugs / case report

References

[1] World Health Organization. HIV/AIDS [Internet]. [cited 30 May 2022]. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/hiv-aids.

[2] Всемирная организация здравоохранения. ВИЧ/СПИД [интернет]. [дата обращения: 30.05.2022]. Доступ по ссылке: https://www.who.int/ru/news-room/fact-sheets/detail/hiv-aids.

[3] Nechaeva OB. Impact of HIV infection epidemic in Russia. Medical Alliance. 2019;7(4):6–16. (In Russ.).

[4] Нечаева О.Б. Эпидемическая ситуация по ВИЧ-инфекции в России // Медицинский альянс. 2019. Т. 7, № 4. С. 6–16.

[5] Nechaeva OB, Podymova AS. Impact of HIV infection on demographic situation in Russia. Medical Alliance. 2018;(1):6–16. (In Russ.).

[6] Нечаева О.Б., Подымова А.С. Влияние ВИЧ-инфекции на демографическую ситуацию в России // Медицинский альянс. 2018. № 1. С. 6–16.

[7] Belyakov NA, Ogurtsova SV, Azovtseva OV, et al. Analysis of the main epidemiological indicators of HIV infection and results of multiyear application of antiretroviral therapy (by the materials from the North-West of Russia). Infectious Diseases: News, Opinions, Training. 2020;9(1):19–27. (In Russ.). doi: 10.33029/2305-3496-2020-9-1-19-27

[8] Беляков Н.А., Огурцова С.В., Азовцева О.В. и др. Анализ основных эпидемиологических показателей ВИЧ-инфекции и результатов многолетнего применения антиретровирусной терапии (по материалам Северо-Запада России) // Инфекционные болезни: новости, мнения, обучение. 2020. Т. 9, № 1. С. 19–27. doi: 10.33029/2305-3496-2020-9-1-19-27

[9] Vostroknutov ME. Analysis of lethal outcomes in patients with HIV/tuberculosis co-infection undergoing inpatient treatment in penitentiaries. Consilium Medicum. 2019;21(3):33–36. (In Russ.). doi: 10.26442/20751753.2019.3.190208

[10] Вострокнутов М.Е. Анализ летальных исходов у пациентов с коинфекцией ВИЧ/туберкулёз, находившихся на стационарном лечении в пенитенциарных учреждениях // Consilium Medicum. 2019. Т. 21, № 3. С. 33–36. doi: 10.26442/20751753.2019.3.190208

[11] Azovtseva OV, Bogacheva TE, Veber VR, Arkhipov GS. Analysis of general cause of death in HIV-infected patients. HIV Infection and Immunosuppressive Disorders. 2018;10(1):84–91. (In Russ.). doi: 10.22328/2077-9828-2018-10-1-84-91

[12] Азовцева О.В., Богачёва Т.Е., Вебер В.Р., Архипов Г.С. Анализ основных причин летальных исходов у ВИЧ-инфицированных больных // ВИЧ-инфекция и иммуносупрессии. 2018. Т. 10, № 1. С. 84–91. doi: 10.22328/2077-9828-2018-10-1-84-91

[13] Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15(11):1369–1377. doi: 10.1097/00002030-200107270-00006

[14] Bartlett J.A., DeMasi R., Quinn J., et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults // AIDS. 2001. Vol. 15, N 11. P. 1369–1377. doi: 10.1097/00002030-200107270-00006

[15] Oette M, Kaiser R, Däumer M, et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr. 2006;41(5):573–581. doi: 10.1097/01.qai.0000214805.52723.c1

[16] Oette M., Kaiser R., Däumer M., et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing // J Acquir Immune Defic Syndr. 2006. Vol. 41, N 5. P. 573–581. 10.1097/01.qai.0000214805.52723.c1

[17] Kravchenko AV, Golokhvastova EL, Vinogradova EN, Volova LYu. Highly active antiretroviral therapy in HIV-infected patients who are multidrug HIV resistant to antiretroviral agents. Epidemiology and Infectious Diseases. 2008;(3):46–51. (In Russ.).

[18] Кравченко А.В., Голохвастова Е.Л., Виноградова Е.Н., Волова Л.Ю. Высокоактивная антиретровирусная терапия у больных ВИЧ-инфекцией с множественной резистентностью ВИЧ к антиретровирусным препаратам // Эпидемиология и инфекционные болезни. 2008. № 3. С. 46–51.

[19] Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72(9):e1–25. doi: 10.2165/11633630-000000000-00000

[20] Tang M.W., Shafer R.W. HIV-1 antiretroviral resistance: scientific principles and clinical applications // Drugs. 2012. Vol. 72, N 9. P. e1–25. doi: 10.2165/11633630-000000000-00000

[21] Bobkova MR. HIV drug resistance. Moscow: Chelovek; 2014. 288 p. (In Russ.).

[22] Бобкова М.Р. Лекарственная устойчивость ВИЧ. Москва: Человек, 2014. 288 с.

[23] Zakharova NG, Dvorak SI, Guba ZV, et al. The causes of unfavorable outcomes among patients taking HAART. Part II. HIV Infection and Immunosuppressive Disorders. 2015;7(4):52–63. (In Russ.).

[24] Захарова Н.Г., Дворак С.И., Губа З.В., и др. Причины неблагоприятных исходов у больных с ВИЧ-инфекцией, принимавших ВААРТ. Часть II // ВИЧ-инфекция и иммуносупрессии. 2015. Т. 7, № 4. С. 52–63.

[25] Lebedeva NN, Zverev SYu, Kulagin VV, et al. HIV drug resistance early warning indicators and their assessment in some regions of Russia. HIV Infection and Immunosuppressive Disorders. 2018;10(4):67–75. (In Russ.). doi: 10.22328/2077-9828-2018-10-4-67-75

[26] Лебедева Н.Н., Зверев С.Я., Кулагин В.В. и др. Индикаторы раннего предупреждения лекарственной устойчивости ВИЧ и их оценка в некоторых регионах России // ВИЧ-инфекция и иммуносупрессии. 2018. Т. 10, № 4. С. 67–75. doi: 10.22328/2077-9828-2018-10-4-67-75

[27] Castagna A, Ferrara M, Galli L, et al; PRESTIGIO Study Group. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. J Antimicrob Chemother. 2018;73(1):177–182. doi: 10.1093/jac/dkx371

[28] Castagna A., Ferrara M., Galli L., et al; PRESTIGIO Study Group. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus // J Antimicrob Chemother. 2018. Vol. 73, N 1. P. 177–182. doi: 10.1093/jac/dkx371

[29] Rusconi S, Adorni F, Tau P, et al; ARCA (Antiviral Response Cohort Analysis). Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). J Clin Virol. 2018;105:112–117. doi: 10.1016/j.jcv.2018.06.012

[30] Rusconi S., Adorni F., Tau P., et al.; ARCA (Antiviral Response Cohort Analysis). Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA) // J Clin Virol. 2018. Vol. 105. P. 112–117. doi: 10.1016/j.jcv.2018.06.012

[31] Castagna A, Maggiolo F, Penco G, et al; VIKING-3 Study Group. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–362. doi: 10.1093/infdis/jiu051

[32] Castagna A., Maggiolo F., Penco G., et al; VIKING-3 Study Group. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study // J Infect Dis. 2014 Vol. 210, N 3. P. 354–362. doi: 10.1093/infdis/jiu051

[33] Akil B, Blick G, Hagins DP, et al; VIKING-4 study team. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther. 2015;20(3):343–348. doi: 10.3851/IMP2878

[34] Akil B., Blick G., Hagins D.P., et al.; VIKING-4 study team. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study // Antivir Ther. 2015. Vol. 20, N 3. P. 343–348. doi: 10.3851/IMP2878

[35] Allavena C, Katlama C, Cotte L, et al; Dat’AIDS Study group. Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1- infected patients. Infect Dis (Lond). 2016;48(5):392–398. doi: 10.3109/23744235.2015.1133927

[36] Allavena C., Katlama C., Cotte L., et al.; Dat’AIDS Study group. Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients // Infect Dis (Lond). 2016. Vol. 48, N 5. P. 392–398. doi: 10.3109/23744235.2015.1133927

[37] New drug for multidrug-resistant HIV. Nat Biotechnol. 2018;36(4):291. doi: 10.1038/nbt0418-291b

[38] New drug for multidrug-resistant HIV // Nat Biotechnol. 2018. Vol. 36, N 4. P. 291. doi: 10.1038/nbt0418-291b

[39] Beccari MV, Mogle BT, Sidman EF, et al. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Antimicrob Agents Chemother. 2019;63(6): e00110–00119. doi: 10.1128/AAC.00110-19

[40] Beccari M.V., Mogle B.T., Sidman E.F., et al. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection // Antimicrob Agents Chemother. 2019. Vol. 63, N 6. P. e00110–00119. doi: 10.1128/AAC.00110-19

[41] Zhang H, Jin R, Yao C, et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther. 2016;13:8. doi: 10.1186/s12981-016-0091-1

[42] Zhang H., Jin R., Yao C., et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients // AIDS Res Ther. 2016. Vol. 13. P. 8. doi: 10.1186/s12981-016-0091-1

[43] Kozal M, Aberg J, Pialoux G, et al.; BRIGHTE Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2020;382(13):1232–1243. doi: 10.1056/NEJMoa1902493

[44] Kozal M., Aberg J., Pialoux G., et al.; BRIGHTE Trial Team. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection // N Engl J Med. 2020. Vol. 382, N 13. P. 1232–1243. doi: 10.1056/NEJMoa1902493

[45] Kirichenko AA, Kireev DE, Lopatukhin AE, et al. Prevalence and structure of HIV-1 drug resistance among treatment naïve patients since the introduction of antiretroviral therapy in the Russian Federation. HIV Infection and Immunosuppressive Disorders. 2019;11(2):75–83. (In Russ.). doi: 10.22328/2077-9828-2019-11-2-75-83

[46] Кириченко А.А., Киреев Д.Е., Лопатухин А.Э., и др. Уровень и структура лекарственной устойчивости ВИЧ-1 среди пациентов без опыта приема антиретровирусных препаратов с момента начала применения антиретровирусной терапии в Российской Федерации» // ВИЧ-инфекция и иммуносупрессии. 2019. Т. 11, № 2. С. 75–83. doi: 10.22328/2077-9828-2019-11-2-75-83

RIGHTS & PERMISSIONS

Nabiullina D.R., Mazus A.I., Litvinova N.G., Khamatova A.A., Nagibina M.V., Chebotareva T.A., Bessarab T.P., Ivannikov E.V., Smirnov N.A., Mashael V.S., Vlatshkaya Y.F.